Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with temozolomide for recurrent glioblastoma
ChiCTR2000028957Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and temozolomide in glioblastoma (GBM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: 6-month progression-free survival and median progression-free survival. Started Feb 2020; status: recruiting.
02
Drugs
anlotinibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000028957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028957.